A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH BIOPSY-CONFIRMED NON-ALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Clesacostat (Primary) ; Ervogastat (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms MIRNA
- Sponsors Pfizer
Most Recent Events
- 02 Apr 2024 Status changed from active, no longer recruiting to completed.
- 16 Mar 2024 This trial has been completed in Slovakia, according to the European Clinical Trials Database record.
- 07 Feb 2024 Planned End Date changed from 22 Feb 2024 to 21 Feb 2024.